| 1 |
Tsuji A, Ikeda Y, Yoshikawa S, Taniguchi K, Sawamura H, Morikawa S, Nakashima M, Asai T, Matsuda S. The Tryptophan and Kynurenine Pathway Involved in the Development of Immune-Related Diseases. IJMS 2023;24:5742. [DOI: 10.3390/ijms24065742] [Reference Citation Analysis]
|
| 2 |
Xu F, Xie Q, Kuang W, Dong Z. Interactions Between Antidepressants and Intestinal Microbiota. Neurotherapeutics 2023. [PMID: 36881351 DOI: 10.1007/s13311-023-01362-8] [Reference Citation Analysis]
|
| 3 |
Yao H, Zhang D, Yu H, Shen H, Liu H, Meng F, Wu X, Zhang G, Wang X. The microbiota-gut-brain axis in pathogenesis of depression: A narrative review. Physiol Behav 2023;260:114056. [PMID: 36528127 DOI: 10.1016/j.physbeh.2022.114056] [Reference Citation Analysis]
|
| 4 |
Hashimoto K. Arketamine for cognitive impairment in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 2023;:1-13. [PMID: 36786865 DOI: 10.1007/s00406-023-01570-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Cheng YJ, Lin CH, Lane HY. Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology 2023;223:109351. [PMID: 36423705 DOI: 10.1016/j.neuropharm.2022.109351] [Reference Citation Analysis]
|
| 6 |
Wang X, Eguchi A, Yang Y, Chang L, Wan X, Shan J, Qu Y, Ma L, Mori C, Yang J, Hashimoto K. Key role of the gut-microbiota-brain axis via the subdiaphragmatic vagus nerve in demyelination of the cuprizone-treated mouse brain. Neurobiol Dis 2023;176:105951. [PMID: 36493975 DOI: 10.1016/j.nbd.2022.105951] [Reference Citation Analysis]
|
| 7 |
Hashimoto K. Neuroinflammation through the vagus nerve-dependent gut–microbiota–brain axis in treatment-resistant depression. Progress in Brain Research 2023. [DOI: 10.1016/bs.pbr.2023.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Wan X, Eguchi A, Sakamoto A, Fujita Y, Yang Y, Qu Y, Hatano M, Mori C, Hashimoto K. Impact of broad-spectrum antibiotics on the gut-microbiota-spleen-brain axis. Brain Behav Immun Health 2023;27:100573. [PMID: 36583066 DOI: 10.1016/j.bbih.2022.100573] [Reference Citation Analysis]
|
| 9 |
Leo H, Kipp M. Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model. Int J Mol Sci 2022;23. [PMID: 36555733 DOI: 10.3390/ijms232416093] [Reference Citation Analysis]
|
| 10 |
Han W, Wang N, Han M, Ban M, Sun T, Xu J. Reviewing the role of gut microbiota in the pathogenesis of depression and exploring new therapeutic options. Front Neurosci 2022;16:1029495. [PMID: 36570854 DOI: 10.3389/fnins.2022.1029495] [Reference Citation Analysis]
|
| 11 |
Ma L, Wang L, Chang L, Shan J, Qu Y, Wang X, Fujita Y, Hashimoto K. A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model. Neuropharmacology 2022;219:109250. [PMID: 36088985 DOI: 10.1016/j.neuropharm.2022.109250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Yoshikawa S, Taniguchi K, Sawamura H, Ikeda Y, Tsuji A, Matsuda S. A New Concept of Associations between Gut Microbiota, Immunity and Central Nervous System for the Innovative Treatment of Neurodegenerative Disorders. Metabolites 2022;12:1052. [DOI: 10.3390/metabo12111052] [Reference Citation Analysis]
|
| 13 |
Lubrich C, Giesler P, Kipp M. Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm. IJMS 2022;23:11342. [DOI: 10.3390/ijms231911342] [Reference Citation Analysis]
|
| 14 |
Hua H, Huang C, Liu H, Xu X, Xu X, Wu Z, Liu C, Wang Y, Yang C. Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota. Neuropharmacology 2022;220:109272. [PMID: 36170927 DOI: 10.1016/j.neuropharm.2022.109272] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 15 |
Zhang JC, Yao W, Hashimoto K. Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Neuropharmacology 2022;218:109219. [PMID: 35977629 DOI: 10.1016/j.neuropharm.2022.109219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 16 |
Schirò G, Iacono S, Ragonese P, Aridon P, Salemi G, Balistreri CR. A Brief Overview on BDNF-Trk Pathway in the Nervous System: A Potential Biomarker or Possible Target in Treatment of Multiple Sclerosis? Front Neurol 2022;13:917527. [DOI: 10.3389/fneur.2022.917527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Wang X, Yang J, Hashimoto K. (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression. Neurosci Biobehav Rev 2022;:104762. [PMID: 35779628 DOI: 10.1016/j.neubiorev.2022.104762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Sawamura H, Taniguchi K, Ikeda Y, Tsuji A, Kitagishi Y, Matsuda S. Gut microbiota could modulate the effects of neuro-immune responses and memory traces via the gut-brain-immune axis in schizophrenia. Explor Neuroprot Ther 2022. [DOI: 10.37349/ent.2022.00019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 19 |
Wei Y, Wang T, Liao L, Fan X, Chang L, Hashimoto K. Brain Research Bulletin Special Issue: Brain–body communication in health and diseases Brain–spleen axis in health and diseases: a review and future perspective. Brain Research Bulletin 2022. [DOI: 10.1016/j.brainresbull.2022.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
